Thymosin Beta-4

Preclinical Only

Also known as: TB-500, Tβ4

Actin-binding peptide

How it works: A naturally occurring peptide that binds actin and is studied in laboratory and early research settings for roles in cell migration and tissue repair. Not FDA-approved.
Known risks: Human clinical safety data are very limited; product purity varies in the compounded/research market.
Contraindications: No established human therapeutic use outside trials.
Drug interactions: Unknown in humans.

Citations

Thymosin beta-4: structure, function, and therapeutic potential (review) (2010) · PMID 20887364

This information is educational only and is not medical advice. A licensed provider makes all clinical decisions. Diadara provides no dosing, reconstitution, or administration guidance.

Thymosin Beta-4 is provided here for education only — it is not currently offered through Diadara. See what we do offer →